These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38679336)

  • 1. Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind.
    Hermans C; Pierce GF
    J Thromb Haemost; 2024 Jul; 22(7):1844-1846. PubMed ID: 38679336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.
    Peters RT; Toby G; Lu Q; Liu T; Kulman JD; Low SC; Bitonti AJ; Pierce GF
    J Thromb Haemost; 2013 Jan; 11(1):132-41. PubMed ID: 23205847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
    von Drygalski A; Chowdary P; Kulkarni R; Susen S; Konkle BA; Oldenburg J; Matino D; Klamroth R; Weyand AC; Jimenez-Yuste V; Nogami K; Poloskey S; Winding B; Willemze A; Knobe K;
    N Engl J Med; 2023 Jan; 388(4):310-318. PubMed ID: 36720133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.
    Turecek PL; Johnsen JM; Pipe SW; O'Donnell JS;
    Haemophilia; 2020 Jul; 26(4):575-583. PubMed ID: 32596930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
    Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
    Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA
    Expert Rev Hematol; 2023; 16(8):567-573. PubMed ID: 37289594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
    Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
    Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
    Castaman G; Linari S
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):143-151. PubMed ID: 29257899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
    Miners AH; Krishnan S; Pasi KJ
    J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.
    Pipe SW; Montgomery RR; Pratt KP; Lenting PJ; Lillicrap D
    Blood; 2016 Oct; 128(16):2007-2016. PubMed ID: 27587878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
    Demers M; Aleman MM; Kistanova E; Peters R; Salas J; Seth Chhabra E
    J Thromb Haemost; 2022 Jul; 20(7):1674-1683. PubMed ID: 35466511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.
    Dumont JA; Liu T; Low SC; Zhang X; Kamphaus G; Sakorafas P; Fraley C; Drager D; Reidy T; McCue J; Franck HW; Merricks EP; Nichols TC; Bitonti AJ; Pierce GF; Jiang H
    Blood; 2012 Mar; 119(13):3024-30. PubMed ID: 22246033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
    Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
    J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Half-life extension technologies for haemostatic agents.
    Mannucci PM
    Thromb Haemost; 2015 Jan; 113(1):165-76. PubMed ID: 25274414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
    Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
    Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications.
    Hazendonk HC; Lock J; Mathôt RA; Meijer K; Peters M; Laros-van Gorkom BA; van der Meer FJ; Driessens MH; Leebeek FW; Fijnvandraat K; Cnossen MH
    J Thromb Haemost; 2016 Mar; 14(3):468-78. PubMed ID: 26714028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.